Entopsis recently signed licensing agreements with a CLIA-certified diagnostic laboratory to commercialize 4 oncology OpsisDx tests in the USA. This represents the first step in bringing OpsisDx to market.
The Entopsis team continues to prove-out the capabilities of OpsisDx for the early detection of other cancers, infectious diseases and mental illnesses. These efforts are aimed at establishing additional partnerships globally for a variety of medical conditions so that we can offer better health outcomes to all people.